Company Filing History:
Years Active: 2008-2012
Title: Innovations in Biomedicine: The Contributions of Inventor Nikolai Malinin
Introduction: Nikolai Malinin is a prominent inventor based in Rehovot, Israel, known for his significant contributions to the field of biomedicine. With a total of three patents to his name, Malinin has focused on developing innovative solutions related to tumor necrosis factor receptor-associated factors, contributing to the advancement of medical science.
Latest Patents: Among his most notable patents is the invention titled "Modulators of TNF receptor associated factor (TRAF), their preparation and use." This patent describes a DNA sequence encoding a protein capable of binding to a TRAF molecule. The invention includes TRAF-binding proteins, their isoforms, analogs, fragments, and derivatives encoded by the DNA sequence, as well as methods for the production of these DNA sequences and proteins. The practical applications of his work have the potential to impact therapeutic approaches significantly.
Career Highlights: Nikolai Malinin works at Yeda Research and Development Co. Ltd., a leading institution known for translating scientific research into viable products. His role at Yeda has allowed him to engage deeply in research and development, pushing the boundaries of current understanding in his field.
Collaborations: Throughout his career, Malinin has collaborated with esteemed colleagues, including David Wallach and Mark Boldin. These collaborations have likely enriched his work and led to advancements in the studies of TRAF-related proteins and their applications in medicine.
Conclusion: In summary, Nikolai Malinin continues to be a driving force in the field of biomedical innovations. His contributions through his patents signify important advancements in therapeutic methods, showcasing the impact of dedicated research and collaboration in the scientific community. The innovations he has developed at Yeda Research and Development Co. Ltd. not only expand our understanding of TRAF proteins but also hold promise for future medical applications.